Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 43 - Drugs for specific purposes, not provided for in groups
Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
11/2002
11/07/2002WO2002088071A1 20-hydroxyeicosatetraenoic acid production inhibitors
11/07/2002WO2002087626A1 Pharmaceutical compositions comprising dendritic cells for immunotherapy of autoimmune disease and treatment methods using the same
11/07/2002WO2002087617A1 Supplementary immunotherapeutics to be used after lung cancer removal
11/07/2002WO2002087616A1 Preventives for postoperative recurrence of premenopausal breast cancer
11/07/2002WO2002087612A2 Use of stimulated peripheral blood mononuclear cells for treating cancerous diseases
11/07/2002WO2002087605A2 Modified fvii in treatment of ards
11/07/2002WO2002087604A2 Preparations containing a combination of vitamin e and afamin
11/07/2002WO2002087600A1 Use of phyllanthus constituents for treating or preventing infections caused by hepatit
11/07/2002WO2002087591A2 Use of derivatives of spironolactone like canrenone as anti-fibrogegic drug
11/07/2002WO2002087590A1 Treatment of psychotic disorders comprising co-therapy with anticonvulsant derivatives and atypical antipsychotics
11/07/2002WO2002087589A1 Medicine for inhibiting drug elimination pump
11/07/2002WO2002087586A1 Sustained release drug delivery system containing codrugs
11/07/2002WO2002087585A1 Compositions comprising lopinavir and methods for enhancing the bioavailability of pharmaceutical agents
11/07/2002WO2002087584A1 Combinations of aldose reductase inhibitors and cyclooxygenase-2 inhibitors
11/07/2002WO2002087575A1 Pharmaceutical combinations based on pyridoindolone derivatives and anticancer agents
11/07/2002WO2002087574A2 Use of pyridoindolone derivatives for preparing anticancer medicines
11/07/2002WO2002087573A1 Crf receptor antagonists
11/07/2002WO2002087565A1 Inhibition of pigmentation by inhibition of fatty acid synthase
11/07/2002WO2002087563A2 Compositions comprising an anti-microtubule agent and a polypeptide or a polysaccharide and the use thereof for the preparation of a medicament for the treatment of inflammatory conditions
11/07/2002WO2002087562A1 Use of protein and essential amino acids to treat amenorrhea and related disorders
11/07/2002WO2002087559A1 Potassium channel opener
11/07/2002WO2002087513A2 Fused heterocyclic inhibitors of phosphodiesterase (pde) 7
11/07/2002WO2002087511A2 Modulators of elastase inhibitor secretion
11/07/2002WO2002087508A2 Nitrosated and nitrosylated nebivolol and its metabolites, compositions and methods of use
11/07/2002WO2002087504A2 Methods for inhibiting tumor cell proliferation
11/07/2002WO2002087472A1 Stent-based delivery of statins to prevent restenosis
11/07/2002WO2002087465A2 Compositions and methods of double-targeting virus infections and cancer cells
11/07/2002WO2002087423A2 Carbonic anhydrase activators for enhancing learning and memory
11/07/2002WO2002087336A1 Foot and mouth disease virus vaccine
11/07/2002WO2002087335A1 Method for treating tumors by the administration of tegafur, uracil, folinic acid, and cyclophosphamide
11/07/2002WO2002069956A3 Use of carnitine for increasing testosteron
11/07/2002WO2002064546A3 Acylated 6,7,8,9-tetrahydro-5h-benzocycloheptenyl amines and their use as pharmaceutical
11/07/2002WO2002055021A3 Glycopolymers and free radical polymerization methods
11/07/2002WO2002044141A3 Substituted imidazoles as dual histamine h1 and h3 agonists or antagonists
11/07/2002WO2002040649A8 Slo2 and slo4, novel potassium channel proteins from human brain
11/07/2002WO2001086002A9 Compositions, kits, and methods for identification, assessment, prevention, and therapy of psoriasis
11/07/2002WO2001085687A1 Substituted indoles as parp inhibitors
11/07/2002WO2001027305A9 Process for producing, methods and compositions of cholesterol lowering agents from higher basidiomycetes mushrooms
11/07/2002WO2001027079A9 Compositions and methods of use of ligands that bind components of the blood coagulation/clotting pathway for the treatment of cancer and angiogenic-based disease
11/07/2002WO2001026676A9 Methods of treating or preventing cell, tissue, and organ damage using human myeloid progenitor inhibitory factor-1 (mpif-1)
11/07/2002WO2001020034A9 Methods and compositions for the screening of cell cycle modulators
11/07/2002WO2001015745A9 Method and formula for tumor remission and suppression of cancer
11/07/2002US20020166132 System for regulating in vivo the expression of a transgene by conditional inhibition
11/07/2002US20020166130 Expression of active human factor IX in mammary tissue of transgenic animals
11/07/2002US20020165412 N-(aryl)-2-arylethenesulfonamides and therapeutic uses thereof
11/07/2002US20020165399 Interphenylene 7-oxabicyclic [2.2.1] heptane oxazoles as prostaglandin F2a antagonists
11/07/2002US20020165378 Human membrane antigen tm4 superfamily protein and dna encoding this protein
11/07/2002US20020165377 ADAM polynucleotides, polypeptides, and antibodies
11/07/2002US20020165365 Synthetic catalyst for selective cleavage of protein and method for selective cleavage of protein using the same
11/07/2002US20020165361 Antibody for use in the diagnosis and treatment of cell proliferation disorders
11/07/2002US20020165347 Polypeptide for use in the diagnosis, prevention and treatment of arteriosclerosis and vascular restenosis
11/07/2002US20020165342 Glucagon-like insulinotropic peptides, compositions and methods
11/07/2002US20020165282 PPAR agonists
11/07/2002US20020165275 Trisubstituted carbocyclic cyclophilin binding compounds and their use
11/07/2002US20020165273 Carbamate compounds for use in preventing or treating neurodegenerative disorders
11/07/2002US20020165268 Use of gamma-tocopherol and its oxidative metabolite LLU-alpha in the treatment of disease
11/07/2002US20020165263 Treatment of fibromyalgia and related fatigue syndromes using antagonists or paritcal agonists of 5HT1a receptors
11/07/2002US20020165262 Methods and products relating to 16-HETE analogs
11/07/2002US20020165257 For patients exhibiting resistance to oncology and chemotherapy with taxanes; antiproliferative agents
11/07/2002US20020165256 Fermentative preparation process for and crystal forms of cytostatics
11/07/2002US20020165255 Prostaglandin agonists such as (3-(methanesulfonylamino-methyl)-phenoxy)-acetic acid methyl ester for preventing/ restoring bone mass loss
11/07/2002US20020165253 Such as N-(4-chlorobenzyl)-8-(4-hydroxybut-1-ynyl)-1-methyl-6-(morpholin-4-ylmethyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide for treatment against herpes viruse; enzyme inhibitors
11/07/2002US20020165247 Use of morphine derivatives as medicaments for the treatment of neuropathic problems
11/07/2002US20020165240 Method of treating proliferative diseases using Eg5 inhibitors
11/07/2002US20020165239 Conjugates of sodium channel blockers and methods of using the same
11/07/2002US20020165235 Alkoxycarbonylamino benzoic acid or alkoxycarbonylamino tetrazolyl phenyl derivatives as IP antagonists
11/07/2002US20020165234 Selective B3 adrenergic agonists
11/07/2002US20020165230 Gamma-ketoacid dipeptides as inhibitors of caspase-3
11/07/2002US20020165223 Eating disorders; anticholesterol agents; hypotensive agents; sleep disorders
11/07/2002US20020165219 Novel heterocycles useful in the treatment of benign prostatic hyperplasia
11/07/2002US20020165209 Low dose estrogen interrupted hormone replacement therapy
11/07/2002US20020165203 Enzyme inhibitors; antiinflammatory agents; rheumatic diseases; antidiabetic agents
11/07/2002US20020165202 Antiinflammatory agents; antiproliferative agents
11/07/2002US20020165201 Cyanoguanidine prodrugs
11/07/2002US20020165200 Central nervous system disorders
11/07/2002US20020165189 Oligoribonucleotides and ribonucleases for cleaving RNA
11/07/2002US20020165164 New effectors of dipeptidyl peptidase IV for topical use
11/07/2002US20020165156 Tumor necrosis factor family and its blocking agent
11/07/2002US20020165155 Crystallization of IGF-1
11/07/2002US20020165131 Histidine-rich glycoprotein
11/07/2002US20020164794 Pluripotent somatic stem cells for use in regenerative medicine
11/07/2002US20020164789 Suppressing glial cell activation in central nervous system; obtain mammal with brain disorder, administer modulator of nervous system activity, evaluate for adjusstment in brain disorder
11/07/2002US20020164767 DNA encoding the human serine protease C-E
11/07/2002US20020164760 Catalytically active recombinant memapsin and methods of use thereof
11/07/2002US20020164758 Enzymatic polypeptide for use in the diagnosis and treatment of allergies, heart and respiratory disorders
11/07/2002US20020164748 Enzymatic polypeptide for use in the treatment of inflammation, autoimmune and tissue rejection disorders
11/07/2002US20020164738 Cell death inhibitory protein
11/07/2002US20020164734 Human pelota homolog
11/07/2002US20020164722 Generating preferential polymerase in sample; obtain nucleotide sequences, incubate in reaction mixture, translate nucleotide sequences, recover polypeptide
11/07/2002US20020164707 Nucleotide sequences coding polypeptide for use in the treatment and diagnosis of cancer, arthrits, pain, diabetes, migraine and inflammation, hypercalcemia, obesity, hypertension, and bone defects
11/07/2002US20020164682 Mammalian cerberus-like protein and compositions
11/07/2002US20020164384 Aquatic animal treatment method and composition containing pimenta extract
11/07/2002US20020164359 Therapeutic composition comprising an antigen or an in vivo generator of a compound comprising an amino acid sequence
11/07/2002US20020164349 Induction apoptosis; west nile virus therapy
11/07/2002US20020164334 Antibody-induced apoptosis
11/07/2002US20020164331 Compositions and methods of monoclonal and polyclonal antibodies specific for T cell subpopulations
11/07/2002US20020164329 Adsorption and removal of endotoxin from physiological fluids using cationic helix peptides
11/07/2002US20020164323 Antithrombin; antiinflammatory agents, rheumatic diseases
11/07/2002US20020164312 Therapeutic method and composition utilizing antigen-antibody complexation and presentation by dendritic cells
11/07/2002US20020164287 Azo compounds for type i phototherapy
1 ... 865 866 867 868 869 870 871 872 873 874 875 876 877 878 879 880 881 882 883 884 885 ... 1564